Treatment With Lilly's Neutralizing Antibodies Bamlanivimab (LY-CoV555) And Btesevimab (LY-CoV016)


Bamlanivimab and etesevimab together also demonstrated statistically significant improvements on all key secondary endpoints, providing strong evidence that the therapy reduced viral load and accelerated symptom resolution


Check out this article to know more right here.

0 comments